A copper(II)-selective chelator ameliorates left-ventricular hypertrophy in type 2 diabetic patients: a randomised placebo-controlled study.
about
Molecular mechanism of action of metformin: old or new insights?Diabetic cardiomyopathy is associated with defective myocellular copper regulation and both defects are rectified by divalent copper chelationDifferential metal content and gene expression in rat left ventricular hypertrophy due to hypertension and hyperactivity.A novel profluorescent probe for detecting oxidative stress induced by metal and H(2)O(2) in living cells.Skin collagen advanced glycation endproducts (AGEs) and the long-term progression of sub-clinical cardiovascular disease in type 1 diabetes.Primary prevention of heart failure.Treatment with a copper-selective chelator causes substantive improvement in cardiac function of diabetic rats with left-ventricular impairmentCopper transporter ATP7A protects against endothelial dysfunction in type 1 diabetic mice by regulating extracellular superoxide dismutase.Protection of the heart by treatment with a divalent-copper-selective chelator reveals a novel mechanism underlying cardiomyopathy in diabetic rats.Trientine reduces BACE1 activity and mitigates amyloidosis via the AGE/RAGE/NF-κB pathway in a transgenic mouse model of Alzheimer's disease.Diabetes and Alzheimer's Disease: Can Elevated Free Copper Predict the Risk of the Disease?Therapeutic potential of copper chelation with triethylenetetramine in managing diabetes mellitus and Alzheimer's disease.EDTA Chelation Therapy to Reduce Cardiovascular Events in Persons with Diabetes.Copper transporters and chaperones: Their function on angiogenesis and cellular signalling.Dicarbonyls and Advanced Glycation End-Products in the Development of Diabetic Complications and Targets for Intervention.Deficient copper concentrations in dried-defatted hepatic tissue from ob/ob mice: A potential model for study of defective copper regulation in metabolic liver disease.Citric acid inhibits development of cataracts, proteinuria and ketosis in streptozotocin (type 1) diabetic rats.Metabolomic analysis of rat serum in streptozotocin-induced diabetes and after treatment with oral triethylenetetramine (TETA).Copper chelation as a potential treatment for left-ventricular hypertrophy in type 2 diabetesPharmacokinetics, pharmacodynamics, and metabolism of triethylenetetramine in healthy human participants: an open-label trial.Complex formation equilibria of Cu(II) and Zn(II) with triethylenetetramine and its mono- and di-acetyl metabolites.Evidence for widespread, severe brain copper deficiency in Alzheimer's dementia.Chelation for diabetes complications: A neglected approach?
P2860
Q22252798-7C5E2BFD-A7E6-463C-8B92-1E5EBF15EF5DQ33804265-2313A150-7747-47E5-9983-8798BC7EED4CQ33849257-63CAB1B0-637E-4936-93AD-62A3001D820DQ34008089-2115E369-6458-4CDA-BD19-31E6040E709EQ36030387-19B375FD-42DC-44D3-8E7C-72DB61C1039CQ36200030-DFD6F5C8-D005-47DA-BE08-2427B1248539Q36698294-2CEB69CA-24ED-4B85-88EB-A74482F55C9FQ37251149-CDD18612-1F22-4C03-94C2-2BFC0D840F99Q37360093-D710B73F-3FC7-40B3-B0E7-938DE485008FQ37406597-190A1B07-BBF8-41DE-8959-F06B96D34F42Q37635602-3A835304-3CE8-4D46-99B5-5BE1F5E10566Q37902643-055199ED-EE5B-4BFB-837A-F04B193144DDQ38585738-7F7DDF9D-AFF4-4CEC-A30B-6805E0CD8777Q38942904-D26A8E5C-A3F0-4DA9-88F4-20D9D8D929BFQ39285661-303C8AE1-2DC6-4A59-83DF-1107DB5E4240Q40526960-9BB2E3F1-E59E-40BA-B0FB-6150DA2F19F9Q42029006-B593B995-6422-4D14-BBD8-251125E8887AQ42096841-0FF775FD-E705-4483-81BA-3305F57FB4CFQ42556808-A2DD6566-3B13-42F0-9381-1F144FBD6F7DQ42648655-A6B9A01F-801D-40D3-A12C-8995732565A3Q42713986-682A9B16-4AB2-4E3A-B976-E8B1998C9262Q47683018-B24780E1-6ABB-42FD-94A0-461E4B6E152CQ53705068-812A2D07-FF2A-4EC4-8CC6-41DB72796B22
P2860
A copper(II)-selective chelator ameliorates left-ventricular hypertrophy in type 2 diabetic patients: a randomised placebo-controlled study.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
A copper(II)-selective chelato ...... ised placebo-controlled study.
@en
type
label
A copper(II)-selective chelato ...... ised placebo-controlled study.
@en
prefLabel
A copper(II)-selective chelato ...... ised placebo-controlled study.
@en
P2093
P2860
P50
P1433
P1476
A copper(II)-selective chelato ...... ised placebo-controlled study.
@en
P2093
A M Dissanayake
A R J Phillips
C J Occleshaw
C M Frampton
G D Gamble
R N Doughty
S D Poppitt
P2860
P2888
P304
P356
10.1007/S00125-009-1265-3
P577
2009-01-27T00:00:00Z